February 8, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Re: MOLECULIN BIOTECH, INC.

Registration Statement on Form S-1 (Registration No. 333-214898) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

Roth Capital Partners, LLC (“Roth”), as underwriter for the referenced offering, hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:30 P.M. (Eastern Time) on February 8, 2017, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Roth affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
ROTH CAPITAL PARTNERS, LLC
By:	/s/ Aaron M. Gurewitz
Name: Aaron M. Gurewitz
Title: Head of Equity Capital Markets